40 results on '"Chadalavada, Kalyani"'
Search Results
2. TERT Copy Number Alterations, Promoter Mutations and Rearrangements in Adrenocortical Carcinomas
3. Chromosomal instability drives metastasis through a cytosolic DNA response
4. Quantifying Y chromosome loss in primary and metastatic prostate cancer by chromosome painting.
5. Immunohistochemistry-based assessment of androgen receptor status and the AR-null phenotype in metastatic castrate resistant prostate cancer
6. Supplementary Table 1 from Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer
7. Supplementary Table 2 from Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer
8. Supplementary Figure 6 from Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer
9. Supplementary Figure 3 from Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer
10. Supplementary Figure 4 from Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer
11. Supplementary Figure 5 from Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer
12. Supplementary Figure 1 from Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer
13. Supplementary Figure 2 from Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer
14. Supplementary Table 3 from Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer
15. Data from Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer
16. Table S8 from Significance of BRCA2 and RB1 Co-loss in Aggressive Prostate Cancer Progression
17. Figure S2 from Significance of BRCA2 and RB1 Co-loss in Aggressive Prostate Cancer Progression
18. ATR inhibition controls aggressive prostate tumors deficient in Y-linked histone demethylase KDM5D
19. Molecular Characterization of Acquired Resistance to KRASG12C-EGFR Inhibition in Colorectal Cancer
20. Error-prone repair of stalled replication forks drives mutagenesis and loss of heterozygosity in haploinsufficient BRCA1 cells
21. Whole-genome single-cell copy number profiling from formalin-fixed paraffin-embedded samples
22. TERT Copy Number Alterations, Promoter Mutations and Rearrangements in Adrenocortical Carcinomas
23. Subtyping of renal cortical neoplasms in fine needle aspiration biopsies using a decision tree based on genomic alterations detected by fluorescence in situ hybridization
24. Novel insights into breast cancer copy number genetic heterogeneity revealed by single-cell genome sequencing
25. Significance of BRCA2 and RB1 Co-loss in Aggressive Prostate Cancer Progression
26. Author response: Novel insights into breast cancer copy number genetic heterogeneity revealed by single-cell genome sequencing
27. A unifying paradigm for transcriptional heterogeneity and squamous features in pancreatic ductal adenocarcinoma
28. Modeling Patient-Derived Glioblastoma with Cerebral Organoids
29. The Genetic Basis of Transcriptional and Spatial Heterogeneity of Squamous Features in Pancreatic Ductal Adenocarcinoma
30. Abstract NG03: Chromosomal instability promotes metastasis through a cytosolic DNA response
31. Intratumoral heterogeneity of ERBB2 amplification and HER2 expression in micropapillary urothelial carcinoma
32. BRCA2-RB1 co-loss and ADT resistance in aggressive prostate cancer.
33. Concurrent deletion of BRCA2 and RB1 and aggressive prostate cancer.
34. Abstract B015: An approach to suppress the evolution of resistance in BRAFV600E-mutant cancer
35. Multi-dimensional genomic analysis of myoepithelial carcinoma identifies prevalent oncogenic gene fusions
36. An approach to suppress the evolution of resistance in BRAFV600E-mutant cancer
37. ATR inhibition controls aggressive prostate tumors deficient in Y-linked histone demethylase KDM5D.
38. Molecular and Clinical Determinants of Acquired Resistance and Treatment Duration for Targeted Therapies in Colorectal Cancer.
39. Molecular Characterization of Acquired Resistance to KRASG12C-EGFR Inhibition in Colorectal Cancer.
40. An approach to suppress the evolution of resistance in BRAF V600E -mutant cancer.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.